Additionally, grades 3–4 irAEs including autoimmune hemolytic anemia, hepatitis, inflammatory colitis and pneumonitis were observed in 7–39% of patients with GI tumors receiving single PD-1/PD-L1 blockade [61, 133, 134]. This evidence concerns the gene CD274 and digestive system neoplasm.